Antileukemic activity and mechanism of drug resistance to the marine salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)

Keyphrases

• Antileukemic Activity 100%
• Drug Resistance Mechanisms 100%
• Protease Inhibitors 100%
• Salinispora Tropica 100%
• Marizomib 100%
• Salinosporamide A 100%
• Bortezomib 50%
• Acquired Resistance 25%
• PSMB5 25%
• Point mutation 16%
• CEM Cells 16%
• Cancer Cells 8%
• Hematological Malignancies 8%
• Acute Lymphoblastic Leukemia 8%
• In Cancer 8%
• Leukemia Cells 8%
• Growth Inhibition 8%
• Catalytic Activity 8%
• Hematologic 8%
• IC50 8%
• Inhibitory Potential 8%
• As(III) 8%
• Proteasome Subunits 8%
• Constitutive Proteasome 8%
• Synergistic Activity 8%
• Treatment Agent 8%
• Immunoproteasome Subunits 8%
• NPI-0052 8%
• Resistance Properties 8%
• Marine Actinobacteria 8%
• CCRF-CEM Cells 8%
• Active Site mutant 8%
• Actinobacteria 8%
• Self-resistance 8%
• Proteasome Inhibitor Bortezomib 8%
• 20S Proteasome Subunit 8%

Biochemistry, Genetics and Molecular Biology

• Drug Resistance 100%
• Proteasome Inhibitor 100%
• Proteasome 50%
• Point Mutation 50%
• Actinobacteria 50%
• Upregulation 25%
• Cancer Cell 25%
• IC50 25%
• Enzymatic Activity 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Resistance 100%
• Proteasome Inhibitor 100%
• Salinosporamide A 100%
• Bortezomib 50%
• Proteasome 14%
• Actinobacteria 14%
• Malignant Neoplasm 7%
• Acute Lymphoblastic Leukemia 7%
• Leukemia 7%
• Hematologic Malignancy 7%
• IC50 7%